Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -233.61 Million CNY | -717.41% |
| 2022 | -114.22 Million CNY | -94.41% |
| 2021 | 257.64 Million CNY | 1668.6% |
| 2020 | -431.77 Million CNY | 107.6% |
| 2019 | -721.08 Million CNY | -186.41% |
| 2018 | -184.45 Million CNY | -32.46% |
| 2017 | 472.73 Million CNY | 8.62% |
| 2016 | 440.85 Million CNY | 3.53% |
| 2015 | 454.25 Million CNY | 105.13% |
| 2014 | 231.62 Million CNY | 50.15% |
| 2013 | 147.77 Million CNY | 55.43% |
| 2012 | 98.85 Million CNY | -3.24% |
| 2011 | 102.09 Million CNY | 59.7% |
| 2010 | 55.43 Million CNY | 36.99% |
| 2009 | 46.7 Million CNY | 79.36% |
| 2008 | 23.72 Million CNY | 92.87% |
| 2007 | 13.5 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 19.22 Million CNY | 118.62% |
| 2024 Q2 | 16.11 Million CNY | 33.23% |
| 2024 Q3 | 2.5 Million CNY | -96.19% |
| 2023 Q3 | -105.73 Million CNY | -86.45% |
| 2023 FY | - CNY | -717.41% |
| 2023 Q2 | -56.71 Million CNY | -402.43% |
| 2023 Q4 | -155.97 Million CNY | -47.52% |
| 2023 Q1 | 18.75 Million CNY | 119.61% |
| 2022 Q1 | 33.02 Million CNY | -90.34% |
| 2022 Q4 | -95.63 Million CNY | -135.44% |
| 2022 Q3 | -40.61 Million CNY | -189.8% |
| 2022 FY | - CNY | -94.41% |
| 2022 Q2 | -14.01 Million CNY | -142.45% |
| 2021 Q3 | -69.18 Million CNY | -154.44% |
| 2021 Q1 | 36.31 Million CNY | 116.59% |
| 2021 Q2 | -27.19 Million CNY | -174.87% |
| 2021 Q4 | 341.82 Million CNY | 594.09% |
| 2021 FY | - CNY | 1668.6% |
| 2020 FY | - CNY | 107.6% |
| 2020 Q4 | -218.9 Million CNY | -1013.05% |
| 2020 Q3 | 23.97 Million CNY | -63.74% |
| 2020 Q2 | 66.11 Million CNY | 38.06% |
| 2020 Q1 | 47.88 Million CNY | 111.56% |
| 2019 Q4 | -414.32 Million CNY | -248.21% |
| 2019 FY | - CNY | -186.41% |
| 2019 Q1 | 71.57 Million CNY | 189.11% |
| 2019 Q2 | 49.8 Million CNY | -30.42% |
| 2019 Q3 | -118.98 Million CNY | -338.92% |
| 2018 Q2 | 153.2 Million CNY | 52.25% |
| 2018 Q1 | 100.62 Million CNY | -35.42% |
| 2018 FY | - CNY | -32.46% |
| 2018 Q4 | -80.32 Million CNY | -189.94% |
| 2018 Q3 | 89.31 Million CNY | -41.7% |
| 2017 Q3 | 78.2 Million CNY | -18.16% |
| 2017 FY | - CNY | 8.62% |
| 2017 Q2 | 95.55 Million CNY | -9.99% |
| 2017 Q1 | 106.17 Million CNY | -7.79% |
| 2017 Q4 | 155.81 Million CNY | 99.23% |
| 2016 Q3 | 146.35 Million CNY | 125.49% |
| 2016 FY | - CNY | 3.53% |
| 2016 Q2 | 64.9 Million CNY | -16.96% |
| 2016 Q1 | 78.16 Million CNY | -56.98% |
| 2016 Q4 | 115.14 Million CNY | -21.33% |
| 2015 Q3 | 102.35 Million CNY | 57.28% |
| 2015 Q4 | 181.68 Million CNY | 77.51% |
| 2015 Q1 | 50.28 Million CNY | -35.05% |
| 2015 Q2 | 65.07 Million CNY | 29.43% |
| 2015 FY | - CNY | 105.13% |
| 2014 Q3 | 62.95 Million CNY | 68.91% |
| 2014 Q4 | 77.42 Million CNY | 22.98% |
| 2014 Q2 | 37.26 Million CNY | 46.88% |
| 2014 Q1 | 25.37 Million CNY | -62.57% |
| 2014 FY | - CNY | 50.15% |
| 2013 Q3 | 26.17 Million CNY | 1.92% |
| 2013 Q1 | 17.65 Million CNY | -44.18% |
| 2013 Q2 | 25.67 Million CNY | 45.45% |
| 2013 Q4 | 67.79 Million CNY | 159.02% |
| 2013 FY | - CNY | 55.43% |
| 2012 Q4 | 31.63 Million CNY | 39.24% |
| 2012 Q1 | 11.36 Million CNY | -79.74% |
| 2012 FY | - CNY | -3.24% |
| 2012 Q2 | 20.58 Million CNY | 81.03% |
| 2012 Q3 | 22.71 Million CNY | 10.37% |
| 2011 Q1 | 13.43 Million CNY | -46.18% |
| 2011 Q2 | 21.92 Million CNY | 63.16% |
| 2011 Q3 | 11.17 Million CNY | -49.03% |
| 2011 Q4 | 56.12 Million CNY | 402.15% |
| 2011 FY | - CNY | 59.7% |
| 2010 FY | - CNY | 36.99% |
| 2010 Q1 | 2.69 Million CNY | 0.0% |
| 2010 Q3 | 12.39 Million CNY | -27.79% |
| 2010 Q2 | 17.15 Million CNY | 537.05% |
| 2010 Q4 | 24.97 Million CNY | 101.53% |
| 2009 FY | - CNY | 79.36% |
| 2008 FY | - CNY | 92.87% |
| 2007 FY | - CNY | 0.0% |